Your browser doesn't support javascript.
loading
Human germline nuclear transfer to overcome mitochondrial disease and failed fertilization after ICSI.
Tang, Maoxing; Boel, Annekatrien; Castelluccio, Noemi; Cardona Barberán, Arantxa; Christodoulaki, Antonia; Bekaert, Bieke; Popovic, Mina; Vanden Meerschaut, Frauke; De Sutter, Petra; Menten, Björn; Symoens, Sofie; Vanlander, Arnaud V; Stoop, Dominic; Coucke, Paul J; Heindryckx, Björn.
Afiliação
  • Tang M; Ghent-Fertility and Stem Cell Team (G-FaST), Department for Reproductive Medicine, Ghent University Hospital, Corneel Heymanslaan 10, 9000, Ghent, Belgium.
  • Boel A; Ghent-Fertility and Stem Cell Team (G-FaST), Department for Reproductive Medicine, Ghent University Hospital, Corneel Heymanslaan 10, 9000, Ghent, Belgium. Annekatrien.Boel@UGent.be.
  • Castelluccio N; Ghent-Fertility and Stem Cell Team (G-FaST), Department for Reproductive Medicine, Ghent University Hospital, Corneel Heymanslaan 10, 9000, Ghent, Belgium.
  • Cardona Barberán A; Ghent-Fertility and Stem Cell Team (G-FaST), Department for Reproductive Medicine, Ghent University Hospital, Corneel Heymanslaan 10, 9000, Ghent, Belgium.
  • Christodoulaki A; Ghent-Fertility and Stem Cell Team (G-FaST), Department for Reproductive Medicine, Ghent University Hospital, Corneel Heymanslaan 10, 9000, Ghent, Belgium.
  • Bekaert B; Ghent-Fertility and Stem Cell Team (G-FaST), Department for Reproductive Medicine, Ghent University Hospital, Corneel Heymanslaan 10, 9000, Ghent, Belgium.
  • Popovic M; Ghent-Fertility and Stem Cell Team (G-FaST), Department for Reproductive Medicine, Ghent University Hospital, Corneel Heymanslaan 10, 9000, Ghent, Belgium.
  • Vanden Meerschaut F; Ghent-Fertility and Stem Cell Team (G-FaST), Department for Reproductive Medicine, Ghent University Hospital, Corneel Heymanslaan 10, 9000, Ghent, Belgium.
  • De Sutter P; Ghent-Fertility and Stem Cell Team (G-FaST), Department for Reproductive Medicine, Ghent University Hospital, Corneel Heymanslaan 10, 9000, Ghent, Belgium.
  • Menten B; Center for Medical Genetics Ghent (CMGG), Department of Biomolecular Medicine, Ghent University Hospital, Corneel Heymanslaan 10, 9000, Ghent, Belgium.
  • Symoens S; Center for Medical Genetics Ghent (CMGG), Department of Biomolecular Medicine, Ghent University Hospital, Corneel Heymanslaan 10, 9000, Ghent, Belgium.
  • Vanlander AV; Division of Paediatric Neurology and Metabolic Diseases, Department of Paediatrics, Ghent University Hospital, Corneel Heymanslaan 10, 9000, Ghent, Belgium.
  • Stoop D; Ghent-Fertility and Stem Cell Team (G-FaST), Department for Reproductive Medicine, Ghent University Hospital, Corneel Heymanslaan 10, 9000, Ghent, Belgium.
  • Coucke PJ; Center for Medical Genetics Ghent (CMGG), Department of Biomolecular Medicine, Ghent University Hospital, Corneel Heymanslaan 10, 9000, Ghent, Belgium.
  • Heindryckx B; Ghent-Fertility and Stem Cell Team (G-FaST), Department for Reproductive Medicine, Ghent University Hospital, Corneel Heymanslaan 10, 9000, Ghent, Belgium.
J Assist Reprod Genet ; 39(3): 609-618, 2022 Mar.
Article em En | MEDLINE | ID: mdl-35064435
ABSTRACT

PURPOSE:

Providing additional insights on the efficacy of human nuclear transfer (NT). Here, and earlier, NT has been applied to minimize transmission risk of mitochondrial DNA (mtDNA) diseases. NT has also been proposed for treating infertility, but it is still unclear which infertility indications would benefit. In this work, we therefore additionally assess the applicability of NT to overcome failed fertilization.

METHODS:

Patient 1 carries a homoplasmic mtDNA mutation (m.11778G > A). Seventeen metaphase II (MII) oocytes underwent pre-implantation genetic testing (PGT), while five MII oocytes were used for spindle transfer (ST), and one in vitro matured (IVM) metaphase I oocyte underwent early pronuclear transfer (ePNT). Patients 2-3 experienced multiple failed intracytoplasmic sperm injection (ICSI) and ICSI-assisted oocyte activation (AOA) cycles. For these patients, the obtained MII oocytes underwent an additional ICSI-AOA cycle, while the IVM oocytes were subjected to ST.

RESULTS:

For patient 1, PGT-M confirmed mutation loads close to 100%. All ST-reconstructed oocytes fertilized and cleaved, of which one progressed to the blastocyst stage. The reconstructed ePNT-zygote reached the morula stage. These samples showed an average mtDNA carry-over rate of 2.9% ± 0.8%, confirming the feasibility of NT to reduce mtDNA transmission. For patient 2-3 displaying fertilization failure, ST resulted in, respectively, 4/5 and 6/6 fertilized oocytes, providing evidence, for the first time, that NT can enable successful fertilization in this patient population.

CONCLUSION:

Our study showcases the repertoire of disorders for which NT can be beneficial, to overcome either mitochondrial disease transmission or failed fertilization after ICSI-AOA.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doenças Mitocondriais / Infertilidade Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doenças Mitocondriais / Infertilidade Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article